Kiora Pharmaceuticals Advances KIO-301 Phase 2 Enrollment Toward Coordinated Global Phase 3 Strategy

Multi-regional regulatory alignment for rare retinal disease programs rarely assembles this early in Phase 2, yet Kiora Pharmaceuticals is already coordinating with partners Théa Open Innovation and Senju Pharmaceutical to frame a potential global Phase 3 registration study for KIO-301, its small-molecule molecular photoswitch for retinitis pigmentosa. For regulatory affairs leads managing multi-jurisdictional submissions, the structure Kiora is building across the U.S., Europe, and Asia warrants close attention.

The company confirmed enrollment has advanced into the 100 µg higher-dose cohort of the randomized, double-masked, controlled Phase 2 ABACUS-2 trial. An independent, predefined safety review will follow treatment of the first patients in that cohort before broader enrollment resumes, a design feature relevant to QA directors tracking adaptive trial oversight mechanisms. Kiora projects last patient, first visit in Q1 2027, with topline data expected in Q3 2027.

The partnership architecture underpinning ABACUS-2 is operationally significant. Théa Open Innovation holds exclusive rights to develop and commercialize KIO-301 in the U.S., Europe, and select non-Asian markets, and fully reimburses Kiora's ABACUS-2 development costs. Senju holds an option covering Japan, China, and select additional Asian territories. South Korea remains the one major territory without a confirmed partner. Kiora has stated that current and potential regional partners could support coordinated global Phase 3 planning, subject to regulatory feedback, a qualifier that places ICH alignment and regional health authority engagement squarely on the near-term agenda.

KIO-104, a non-steroidal DHODH inhibitor designed for intravitreal administration, is enrolling patients in the higher-dose cohort of the Phase 2 KLARITY trial in macular edema due to retinal inflammation. Initial clinical data are expected in late 2026, intended to assess activity across retinal inflammatory conditions and inform the next development stage. The compound has been well tolerated based on safety data available to date.

On the financial side, Kiora ended Q2 2026 with approximately $16.8 million in cash and short-term investments, with an operating runway projected into late 2028. A private placement secured up to $24.0 million in gross proceeds, including $5.0 million received upfront; remaining proceeds are contingent on near-term milestone-based warrant exercises. The company is also evaluating strategic transactions that could expand its pipeline, with a warrant acceleration milestone tied to completion of a transaction by early 2027.

The Q3 2027 topline readout from ABACUS-2 will serve as the primary decision gate for whether Kiora and its regional partners proceed to global Phase 3 design discussions with regulators.

Source: Kiora Pharmaceuticals, Inc. via ir.kiorapharma.com, August 7, 2026.